These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24335103)

  • 21. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
    Wendtner CM; Hallek M; Fraser GA; Michallet AS; Hillmen P; Dürig J; Kalaycio M; Gribben JG; Stilgenbauer S; Buhler A; Kipps TJ; Purse B; Zhang J; De Bedout S; Mei J; Chanan-Khan A
    Leuk Lymphoma; 2016; 57(6):1291-9. PubMed ID: 26763349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
    Ogura M; Imaizumi Y; Uike N; Asou N; Utsunomiya A; Uchida T; Aoki T; Tsukasaki K; Taguchi J; Choi I; Maruyama D; Nosaka K; Chen N; Midorikawa S; Ohtsu T; Tobinai K
    Lancet Haematol; 2016 Mar; 3(3):e107-18. PubMed ID: 26947199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
    Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
    Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
    Kennedy GA; Seymour JF; Wolf M; Januszewicz H; Davison J; McCormack C; Ryan G; Prince HM
    Eur J Haematol; 2003 Oct; 71(4):250-6. PubMed ID: 12950233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
    Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
    Nabhan C; Patel A; Villines D; Tolzien K; Kelby SK; Lestingi TM
    Clin Genitourin Cancer; 2014 Feb; 12(1):27-32. PubMed ID: 24238760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
    Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
    Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
    Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
    J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.
    Goy A; Kalayoglu Besisik S; Drach J; Ramchandren R; Robertson MJ; Avivi I; Rowe JM; Herbrecht R; Van Hoof A; Zhang L; Cicero S; Fu T; Witzig T
    Br J Haematol; 2015 Aug; 170(4):496-503. PubMed ID: 25921098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome.
    Furue M; Kadono T
    J Dermatol; 2015 Oct; 42(10):941-4. PubMed ID: 26432429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
    Corbin ZA; Nguyen-Lin A; Li S; Rahbar Z; Tavallaee M; Vogel H; Salva KA; Wood GS; Kim YH; Nagpal S
    J Neurooncol; 2017 May; 132(3):439-446. PubMed ID: 28271282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
    Cortés-Hernández J; Ávila G; Vilardell-Tarrés M; Ordi-Ros J
    Arthritis Res Ther; 2012 Dec; 14(6):R265. PubMed ID: 23217273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
    Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
    Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
    Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome).
    Jones GW; Rosenthal D; Wilson LD
    Cancer; 1999 May; 85(9):1985-95. PubMed ID: 10223240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
    Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
    J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.